Use of Melatonin for Neuroprotection in Asphyxiated Newborns

Status Recruiting

Clinical Trial Summary

Protection of brain development is a major aim in the Neonatal Intensive Care Unit. Hypoxic-Ischemic Encephalopathy (HIE) occurs in 3-5 per 1000 births. Only 47% of neonates have normal outcomes. The neurodevelopmental consequences of brain injury for asphyxiated term infants include cerebral palsy, severe intellectual disabilities and also a number of minor behavioural and cognitive deficits. However, there are very few therapeutic strategies for the prevention or treatment of brain damage. The gold standard is hypothermic treatment but, according to the literature, melatonin potentially acts in synergy with hypothermia for neuroprotection and to improve neurologic outcomes. Melatonin appears to be a good candidate because of its different protective effects including reactive oxygen species scavenging, excitotoxic cascade blockade, modulation of neuroinflammatory pathways.

The research study will evaluate the neuroprotective properties and the effects of Melatonin in association with therapeutic hypothermia for hypoxic ischemic encephalopathy.

Clinical Trial Description

It is a randomized double blind, placebo controlled trial on 100 neonates with moderate to moderately to severe hypoxic ischemic encephalopathy (HIE) . HIE infants are randomized into two groups: Whole body cooling group (N = 50 receive 72 hours of whole body hypothermia) and melatonin/ hypothermia group (N = 50; receive hypothermia and 5 daily enteral doses of melatonin 10 mg/kg). Serum melatonin and autophagy levels are measured at enrollment, daily during the hypothermic treatment, at day 5 and 7 for the two HIE groups.

aEEG will be performed for 72 hrs during the hypothermic treatment and the re-warming. MRI and Spectroscopy analysis will be performed between day 5 and 7 of. After hospital discharge the infants will enter a follow-up program consisting in periodic clinical and developmental assessments until 2 years of age corrected for prematurity. An expert psychologist and a neonatologist will assess neurodevelopmental outcome using the Bayley Scales III at 6-12-24 months of corrected age. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03806816
Study type	Interventional
Source	University Hospital of Ferrara
Contact	Anna Tarocco, MD
Phone	+390532236014
Email	anna.tarocco@unife.it
Status	Recruiting
Phase	N/A
Start date	December 13, 2018
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05048550` - Babies in Glasses; a Feasibility Study.	N/A
Recruiting	`NCT05514340` - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy	Phase 2
Recruiting	`NCT05836610` - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates	Phase 4
Completed	`NCT03024021` - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed	`NCT01913340` - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)	Phase 1/Phase 2
Enrolling by invitation	`NCT02260271` - Florida Neonatal Neurologic Network
Terminated	`NCT01192776` - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)	N/A
Completed	`NCT06344286` - The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE	N/A
Recruiting	`NCT05901688` - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting	`NCT02894866` - Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy	N/A
Recruiting	`NCT03657394` - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries	N/A
Recruiting	`NCT03682042` - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up	N/A
Withdrawn	`NCT03681314` - Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU)	N/A
Completed	`NCT03485781` - Propofol-induced EEG Changes in Hypoxic Brain Injury
Not yet recruiting	`NCT06429007` - A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury	Phase 2
Recruiting	`NCT05568264` - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit	N/A
Not yet recruiting	`NCT06448780` - Dose Optimization of Caffeine for HIE	Phase 1
Completed	`NCT02264808` - Developmental Outcomes
Completed	`NCT05687708` - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia	N/A
Recruiting	`NCT06195345` - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Use of Melatonin for Neuroprotection in Asphyxiated Newborns — MELPRO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms